Kinnate Biopharma Inc.
KNTE · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.15 | -0.09 | -0.06 | -0.26 |
| FCF Yield | -90.63% | -34.13% | -9.30% | -1.76% |
| EV / EBITDA | -0.48 | -2.07 | -7.30 | -37.98 |
| Quality | ||||
| ROIC | -73.23% | -45.13% | -25.42% | -9.15% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.89 | 0.77 | 0.79 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -9.04% | -27.73% | -135.69% | -189.55% |
| Safety | ||||
| Net Debt / EBITDA | 0.46 | 0.21 | 1.29 | 10.17 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -927.80 | -1,794.78 | -9,341.63 | -17,326.51 |